SEC Form 4 · accession 0001019056-18-000433
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane A Gross
Officer — See Remarks
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 9:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2018 | M | 9,728 | — | A | 105,437 | D | |
| Common Stock | Mar 9, 2018 | F | 2,282 | $3.13 | D | 103,155 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (Right to Buy)F2 | $3.13 | Mar 9, 2018 | A | 67,400 | A | — | Mar 9, 2028 | Common Stock | 67,400 | 67,400 | D |
| Restricted Stock UnitF1,F3 | — | Mar 9, 2018 | M | 9,728 | D | — | — | Common Stock | 9,728 | 9,138 | D |
Explanation of responses
- F1Each RSU converts into the Issuer's common stock on a one-for-one basis.
- F2On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.
- F3The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018.
Remarks
Title - SVP, Research and Non-Clinical Development